Christina Demuth

936 total citations
30 papers, 677 citations indexed

About

Christina Demuth is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Christina Demuth has authored 30 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Cancer Research, 19 papers in Oncology and 14 papers in Pathology and Forensic Medicine. Recurrent topics in Christina Demuth's work include Cancer Genomics and Diagnostics (19 papers), Genetic factors in colorectal cancer (14 papers) and Lung Cancer Treatments and Mutations (11 papers). Christina Demuth is often cited by papers focused on Cancer Genomics and Diagnostics (19 papers), Genetic factors in colorectal cancer (14 papers) and Lung Cancer Treatments and Mutations (11 papers). Christina Demuth collaborates with scholars based in Denmark, United States and France. Christina Demuth's co-authors include Boe Sandahl Sørensen, Peter Meldgaard, Kristine Raaby Jakobsen, Anders Lade Nielsen, Anne Tranberg Madsen, Britta Weber, Anne Winther‐Larsen, Claus L. Andersen, Karen‐Lise Garm Spindler and Mads H. Rasmussen and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Scientific Reports.

In The Last Decade

Christina Demuth

28 papers receiving 674 citations

Peers

Countries citing papers authored by Christina Demuth

Since Specialization

Citations

This map shows the geographic impact of Christina Demuth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christina Demuth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christina Demuth more than expected).

Fields of papers citing papers by Christina Demuth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christina Demuth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christina Demuth. The network helps show where Christina Demuth may publish in the future.

Co-authorship network of co-authors of Christina Demuth

This figure shows the co-authorship network connecting the top 25 collaborators of Christina Demuth. A scholar is included among the top collaborators of Christina Demuth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christina Demuth. Christina Demuth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Whole‐genome sequencing of cell‐free DNA reveals DNA of tumor origin in plasma from patients with colorectal adenomas 2025 ·Molecular Oncology ·Amanda Frydendahl, Adam J. Widman, (unknown), (unknown), (unknown), Jesper Nors, Johanne Ahrenfeldt, Tenna Vesterman Henriksen, Christina Demuth, Line Raaby, Mads H. Rasmussen, Christina Therkildsen, Dan A. Landau, Claus L. Andersen	0
2	Timing of ctDNA Analysis Aimed at Guiding Adjuvant Treatment in Colorectal Cancer 2025 ·Clinical Cancer Research ·Tenna Vesterman Henriksen, Christina Demuth, Amanda Frydendahl, Jesper Nors, (unknown), Mads H. Rasmussen, Ole H. Larsen, (unknown), (unknown), (unknown), (unknown), Ole Thorlacius‐Ussing, (unknown), (unknown), (unknown), Nis H. Schlesinger, Lene Hjerrild Iversen, Kåre Andersson Gotschalck, Claus L. Andersen	2
3	Error-Corrected Deep Targeted Sequencing of Circulating Cell-Free DNA from Colorectal Cancer Patients for Sensitive Detection of Circulating Tumor DNA 2024 ·International Journal of Molecular Sciences ·Amanda Frydendahl, Mads H. Rasmussen, Sarah Østrup Jensen, Tenna Vesterman Henriksen, Christina Demuth, (unknown), Henrik J. Ditzel, (unknown), Jakob Skou Pedersen, Lars Dyrskjøt, Claus L. Andersen	6
4	Beyond basics: Key mutation selection features for successful tumor‐informed ctDNA detection 2024 ·International Journal of Cancer ·(unknown), Mads H. Rasmussen, Tenna Vesterman Henriksen, Christina Demuth, Amanda Frydendahl, Iver Nordentoft, Lars Dyrskjøt, Claus L. Andersen	6
5	DREAMS: deep read-level error model for sequencing data applied to low-frequency variant calling and circulating tumor DNA detection 2023 ·Genome biology ·(unknown), (unknown), Mads H. Rasmussen, Amanda Frydendahl, Iben Lyskjær, Christina Demuth, Jesper Nors, Kåre Andersson Gotschalck, Lene Hjerrild Iversen, Claus L. Andersen, Jakob Skou Pedersen	5
6	Impact of Whole Genome Doubling on Detection of Circulating Tumor DNA in Colorectal Cancer 2023 ·Cancers ·(unknown), Tenna Vesterman Henriksen, Christina Demuth, Amanda Frydendahl, Mads H. Rasmussen, Jesper Nors, Nicolai J. Birkbak, Anders Husted Madsen, (unknown), (unknown), (unknown), Alessio Monti, Ole Thorlacius‐Ussing, Mikail Gögenur, (unknown), Nis H. Schlesinger, (unknown), Lene Hjerrild Iversen, Kåre Andersson Gotschalck, Claus L. Andersen	10
7	Comparing single‐target and multitarget approaches for postoperative circulating tumour DNA detection in stage II–III colorectal cancer patients 2022 ·Molecular Oncology ·Tenna Vesterman Henriksen, Thomas Reinert, Mads H. Rasmussen, Christina Demuth, (unknown), Anders Husted Madsen, Kåre Andersson Gotschalck, Lene Hjerrild Iversen, Claus L. Andersen	11
8	cGAS-STING pathway expression as a prognostic tool in NSCLC 2021 ·Translational Lung Cancer Research ·(unknown), Birgitte Sandfeld‐Paulsen, (unknown), Christina Demuth, Peter Meldgaard, Boe Sandahl Sørensen, Kristine Raaby Jakobsen	21
9	Development of blood-based biomarker tests for early detection of colorectal neoplasia: Influence of blood collection timing and handling procedures 2020 ·Clinica Chimica Acta ·(unknown), (unknown), Jon J. Ladd, Paul D. Lampe, Robert S. Bresalier, Gerard J. Davis, Christina Demuth, Sarah Østrup Jensen, Claus L. Andersen, (unknown), Ib Jarle Christensen, Hans Jørgen Nielsen	12
10	Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing 2018 ·Translational Oncology ·Christina Demuth, Karen‐Lise Garm Spindler, Julia S. Johansen, Niels Pallisgaard, Dorte Nielsen, Estrid Høgdall, (unknown), Boe Sandahl Sørensen	58
11	Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients 2017 ·British Journal of Cancer ·Anne Winther‐Larsen, Christina Demuth, (unknown), Anne Tranberg Madsen, Karin Hjorthaug, Peter Meldgaard, Boe Sandahl Sørensen	45
12	MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells 2017 ·Oncogenesis ·Kristine Raaby Jakobsen, Christina Demuth, Anne Tranberg Madsen, Dianna Hussmann, (unknown), Anders Lade Nielsen, Boe Sandahl Sørensen	44
13	P-007 Comparison of methods for measuring total cell-free DNA and KRAS mutations in plasma from metastatic colorectal cancer patients 2016 ·Annals of Oncology ·Christina Demuth, K.-L.G. Spindler, Julia S. Johansen, Niels Pallisgaard, Dorte Nielsen, (unknown), (unknown), (unknown)	1
14	The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer 2016 ·Translational Lung Cancer Research ·Kristine Raaby Jakobsen, Christina Demuth, Boe Sandahl Sørensen, Anders Lade Nielsen	88
15	Ultra-micro samples can be used for mRNA quantification of lung cancer biomarkers 2016 ·Scandinavian Journal of Clinical and Laboratory Investigation ·Birgitte Sandfeld‐Paulsen, Christina Demuth, Birgitte Holst Folkersen, Torben Riis Rasmussen, Line Bille Madsen, Boe Sandahl Sørensen, Peter Meldgaard	2
16	Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients 2016 ·Translational Oncology ·Anne Winther‐Larsen, (unknown), Christina Demuth, (unknown), Peter Meldgaard, Boe Sandahl Sørensen	12
17	Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib 2016 ·Lung Cancer ·(unknown), Christina Demuth, Britta Weber, Boe Sandahl Sørensen, Peter Meldgaard	96
18	Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy 2015 ·Stem Cells International ·Ninna Aggerholm‐Pedersen, Christina Demuth, Akmal Safwat, Peter Meldgaard, Moustapha Kassem, Boe Sandahl Sørensen	14
19	Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib 2015 ·Lung Cancer ·Anne Winther‐Larsen, Peter H. Nissen, Kristine Raaby Jakobsen, Christina Demuth, Boe Sandahl Sørensen, Peter Meldgaard	14
20	Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma 2007 ·European Journal of Surgical Oncology ·Christian Möbius, Christina Demuth, Thomas Aigner, Marcus Wiedmann, Christian Wittekind, Joachim Mössner, Johann Hauss, Helmut Witzigmann	58

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact